PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

Inclusion Criteria: * Women with postmenopausal osteoporosis or osteopenia * Discontinuation of daily and /or weekly alendronate or risedronate therapy because of GI intolerance (eg, heartburn, acid reflux, stomach upset) Exclusion Criteria: * Inability to stand or sit upright for 60 minutes * Inability to swallow a tablet whole - Hypersensitivity to any component of Boniva * Malignant disease diagnosed within previous 10 years (except resected basal cell cancer); contraindications for calcium or vitamin D therapy * Patients who do not fulfill a minimum 3 months wash-out therapy from any previous bisphosphonate therapy